Company Interview / Biome forecasting a culture of growth

Biome Australia (ASX:BIO) anticipates record sales of over $5.5 million for the first quarter of FY26, surpassing the prior quarter’s $5 million. Founder and MD Blair Norfolk shares that robust performance in the probiotic sector, supported by strong clinical trials and limited competition, positions Biome Australia (ASX:BIO) as a leader in pharmacy distribution. The company reports year-on-year growth rates of 40%, 50%, and even 60% across channels, now ranking second in pharmacy revenue and first for growth over the past five years. Norfolk attributes this to Biome’s premium healthcare model and active support from over 6,000 distribution points, including pharmacies and independent health professionals across Australia.

Norfolk outlines key drivers for future growth, noting recently secured distribution partnerships: a major New Zealand expansion with Pro Pharma, a subsidiary of $EBOS, and Green Cross Health, as well as deals in Ireland. The launch of Biome’s activated probiotics into Mecca’s new Melbourne flagship—targeting skin health for acne and eczema—marks an entrance into premium skincare retail. Norfolk views this as a significant opportunity to appeal to new customer segments.

After achieving its first net profit post-IPO in November 2021, Norfolk confirms Biome’s commitment to maintaining profitability while pursuing further growth in Australia, the UK, Ireland, Canada, and New Zealand, with strategic plans for further product and market expansion.